MET and neoplasm: The previous left femur tissue specimen was sent for molecular testing, which showed a PDL-1 (22c3) tumor proportion score of 50%, high tumor mutation burden (11 mutation/megabase), and METex14 skipping mutation, suggesting the benefit of using MET inhibitors, e.g., capmatinib or tepotinib.